Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
Identifieur interne : 000234 ( Main/Exploration ); précédent : 000233; suivant : 000235Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
Auteurs : Salaheddin M. Mahmud [Canada] ; Songul Bozat-Emre [Canada] ; Gregory Hammond [Canada] ; Lawrence Elliott [Canada] ; Paul Van Caeseele [Canada]Source :
- PloS one [ 1932-6203 ] ; 2015.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (MeSH), Admission du patient (MeSH), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Enregistrements (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Grippe humaine (épidémiologie), Hospitalisation (MeSH), Humains (MeSH), Jeune adulte (MeSH), Manitoba (MeSH), Mâle (MeSH), Nourrisson (MeSH), Pandémies (MeSH), Pneumopathie infectieuse (prévention et contrôle), Pneumopathie infectieuse (épidémiologie), Programmes de vaccination (MeSH), Risque (MeSH), Sous-type H1N1 du virus de la grippe A (immunologie), Sujet âgé (MeSH), Vaccins antigrippaux (immunologie), Études cas-témoins (MeSH).
- MESH :
- immunologie : Sous-type H1N1 du virus de la grippe A, Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine, Pneumopathie infectieuse.
- épidémiologie : Grippe humaine, Pneumopathie infectieuse.
- Adjuvants immunologiques, Admission du patient, Adolescent, Adulte, Adulte d'âge moyen, Enfant, Enfant d'âge préscolaire, Enregistrements, Femelle, Hospitalisation, Humains, Jeune adulte, Manitoba, Mâle, Nourrisson, Pandémies, Programmes de vaccination, Risque, Sujet âgé, Études cas-témoins.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (MeSH), Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Hospitalization (MeSH), Humans (MeSH), Immunization Programs (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (immunology), Influenza Vaccines (immunology), Influenza, Human (epidemiology), Influenza, Human (prevention & control), Male (MeSH), Manitoba (MeSH), Middle Aged (MeSH), Pandemics (MeSH), Patient Admission (MeSH), Pneumonia (epidemiology), Pneumonia (prevention & control), Registries (MeSH), Risk (MeSH), Young Adult (MeSH).
- MESH :
- chemical , immunology : Influenza Vaccines.
- chemical : Adjuvants, Immunologic.
- geographic : Manitoba.
- epidemiology : Influenza, Human, Pneumonia.
- immunology : Influenza A Virus, H1N1 Subtype.
- prevention & control : Influenza, Human, Pneumonia.
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Female, Hospitalization, Humans, Immunization Programs, Infant, Male, Middle Aged, Pandemics, Patient Admission, Registries, Risk, Young Adult.
Abstract
BACKGROUND
The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization.
METHODS
A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry.
RESULTS
Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among <4 year-olds (928) and ≥65 years (1,721). VE against hospitalization with laboratory-confirmed A(H1N1)pdm09 was 70% (39-85%) overall and (91%; 62-98%) ≥ 14 days following vaccination.
DISCUSSION
Our data suggest that the adjuvanted A(H1N1)pdm09 vaccine was effective in preventing about 55-60% of P&I hospitalizations among children and younger adults who were at much higher risk of infection. Unfortunately, the vaccine was less effective among 65 or older adults. Despite that the vaccine still had a significant population-based impact especially among the very young (<5) and the older (≥ 65 years).
DOI: 10.1371/journal.pone.0142754
PubMed: 26600435
PubMed Central: PMC4658136
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?</title><author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Winnipeg Regional Health Authority, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicine, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Winnipeg Regional Health Authority, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cadham Provincial Laboratory, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26600435</idno><idno type="pmid">26600435</idno><idno type="doi">10.1371/journal.pone.0142754</idno><idno type="pmc">PMC4658136</idno><idno type="wicri:Area/Main/Corpus">000174</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000174</idno><idno type="wicri:Area/Main/Curation">000174</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000174</idno><idno type="wicri:Area/Main/Exploration">000174</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?</title><author><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Winnipeg Regional Health Authority, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medicine, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation></author><author><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><affiliation wicri:level="4"><nlm:affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Winnipeg Regional Health Authority, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author><author><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><affiliation wicri:level="4"><nlm:affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba</wicri:regionArea><orgName type="university">Université du Manitoba</orgName><placeName><settlement type="city">Winnipeg</settlement><region type="state">Manitoba</region></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Cadham Provincial Laboratory, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation><affiliation wicri:level="1"><nlm:affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Manitoba Health, Winnipeg, Manitoba</wicri:regionArea><wicri:noRegion>Manitoba</wicri:noRegion></affiliation></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (MeSH)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Case-Control Studies (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Female (MeSH)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Immunization Programs (MeSH)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (immunology)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Manitoba (MeSH)</term><term>Middle Aged (MeSH)</term><term>Pandemics (MeSH)</term><term>Patient Admission (MeSH)</term><term>Pneumonia (epidemiology)</term><term>Pneumonia (prevention & control)</term><term>Registries (MeSH)</term><term>Risk (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (MeSH)</term><term>Admission du patient (MeSH)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Enregistrements (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (épidémiologie)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Manitoba (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Pandémies (MeSH)</term><term>Pneumopathie infectieuse (prévention et contrôle)</term><term>Pneumopathie infectieuse (épidémiologie)</term><term>Programmes de vaccination (MeSH)</term><term>Risque (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (immunologie)</term><term>Sujet âgé (MeSH)</term><term>Vaccins antigrippaux (immunologie)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adjuvants, Immunologic</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Manitoba</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Case-Control Studies</term><term>Child</term><term>Child, Preschool</term><term>Female</term><term>Hospitalization</term><term>Humans</term><term>Immunization Programs</term><term>Infant</term><term>Male</term><term>Middle Aged</term><term>Pandemics</term><term>Patient Admission</term><term>Registries</term><term>Risk</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Admission du patient</term><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Enregistrements</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Jeune adulte</term><term>Manitoba</term><term>Mâle</term><term>Nourrisson</term><term>Pandémies</term><term>Programmes de vaccination</term><term>Risque</term><term>Sujet âgé</term><term>Études cas-témoins</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among <4 year-olds (928) and ≥65 years (1,721). VE against hospitalization with laboratory-confirmed A(H1N1)pdm09 was 70% (39-85%) overall and (91%; 62-98%) ≥ 14 days following vaccination.</p></div><div type="abstract" xml:lang="en"><p><b>DISCUSSION</b></p><p>Our data suggest that the adjuvanted A(H1N1)pdm09 vaccine was effective in preventing about 55-60% of P&I hospitalizations among children and younger adults who were at much higher risk of infection. Unfortunately, the vaccine was less effective among 65 or older adults. Despite that the vaccine still had a significant population-based impact especially among the very young (<5) and the older (≥ 65 years).</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26600435</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>23</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>11</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?</ArticleTitle><Pagination><MedlinePgn>e0142754</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0142754</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The extent to which A(H1N1)pdm09 influenza vaccines prevented hospital admissions with pneumonia and influenza (P&I) during the 2009 pandemic remains poorly understood. We evaluated the effectiveness of the A(H1N1)pdm09 and seasonal influenza vaccines (TIV) used during the 2009 mass vaccination campaign in Manitoba (Canada) in preventing P&I hospitalization.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A population-based record-linkage nested case-control study. Cases (N = 1,812) were persons hospitalized with influenza (ICD-10:J09-J11) or pneumonia (ICD-10:J12-J18) during the study period. Age-, gender- and area of residence-matched controls (N = 7,915) were randomly sampled from Manitoba's Population Registry. Information on receipt of A(H1N1)pdm09 vaccine and TIV was obtained from the Manitoba Immunization Monitoring System, a province-wide vaccine registry.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, the adjuvanted A(H1N1)pdm09 vaccine was 27% (95%CI 13-39%) effective against P&I hospitalization ≥ 14 days following administration. Effectiveness seemed lower among older (≥ 65 years) adults (10%; -16-30%), particularly when compared to under-5 children (58%; 30-75%). The number-needed-to-vaccinate to prevent 1 P&I admission was lowest among <4 year-olds (928) and ≥65 years (1,721). VE against hospitalization with laboratory-confirmed A(H1N1)pdm09 was 70% (39-85%) overall and (91%; 62-98%) ≥ 14 days following vaccination.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our data suggest that the adjuvanted A(H1N1)pdm09 vaccine was effective in preventing about 55-60% of P&I hospitalizations among children and younger adults who were at much higher risk of infection. Unfortunately, the vaccine was less effective among 65 or older adults. Despite that the vaccine still had a significant population-based impact especially among the very young (<5) and the older (≥ 65 years).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mahmud</LastName><ForeName>Salaheddin M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bozat-Emre</LastName><ForeName>Songul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammond</LastName><ForeName>Gregory</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elliott</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Caeseele</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cadham Provincial Laboratory, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Manitoba Health, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>11</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017589" MajorTopicYN="N">Immunization Programs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008350" MajorTopicYN="N" Type="Geographic">Manitoba</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>09</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26600435</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0142754</ArticleId><ArticleId IdType="pii">PONE-D-15-39178</ArticleId><ArticleId IdType="pmc">PMC4658136</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Public Health. 1994 Oct;84(10):1666-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7943493</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2011 Sep;5(5):299-305</Citation><ArticleIdList><ArticleId IdType="pubmed">21668694</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Geriatr Soc. 1999 Jun;47(6):749-54</Citation><ArticleIdList><ArticleId IdType="pubmed">10366179</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2011 Nov;128(5):e1084-91</Citation><ArticleIdList><ArticleId IdType="pubmed">21987710</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Technol Assess. 2010 Jul;14(34):313-46</Citation><ArticleIdList><ArticleId IdType="pubmed">20630126</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1998 Nov;32(11):1152-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9825079</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 2009 Sep 1;170(5):650-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19625341</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2011 Jan 25;344:d7901</Citation><ArticleIdList><ArticleId IdType="pubmed">22277542</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2010 Jul 12;28(31):4895-902</Citation><ArticleIdList><ArticleId IdType="pubmed">20553769</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1996 Jan;49(1):51-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8598511</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Rep. 2010 Dec;21(4):63-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21269013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 2009 Dec;47(12):3805-13</Citation><ArticleIdList><ArticleId IdType="pubmed">19794033</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2012 Jul 1;206(1):49-55</Citation><ArticleIdList><ArticleId IdType="pubmed">22551808</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1998 Jan;36(1):8-27</Citation><ArticleIdList><ArticleId IdType="pubmed">9431328</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Oct 19;29(45):7975-81</Citation><ArticleIdList><ArticleId IdType="pubmed">21884747</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Gastroenterol. 2009 Dec;104(12):3015-23</Citation><ArticleIdList><ArticleId IdType="pubmed">19809413</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Oct 5;182(14):1522-4</Citation><ArticleIdList><ArticleId IdType="pubmed">20823167</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1997 Sep;35(9):932-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9298082</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2010 Apr 06;7(4):e1000259</Citation><ArticleIdList><ArticleId IdType="pubmed">20386730</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1993 Mar;31(3):201-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8450678</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Infect Dis Med Microbiol. 2012 Summer;23(2):65-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23730311</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 2002 Aug;40(8):675-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12187181</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2011 Jan 1;52 Suppl 1:S13-26</Citation><ArticleIdList><ArticleId IdType="pubmed">21342884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Database Syst Rev. 2010 Feb 17;(2):CD004876</Citation><ArticleIdList><ArticleId IdType="pubmed">20166072</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Jun 16;338:b2137</Citation><ArticleIdList><ArticleId IdType="pubmed">19531550</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Infect Dis. 2011 Jul 18;11:196</Citation><ArticleIdList><ArticleId IdType="pubmed">21767348</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoepidemiol Drug Saf. 2004 Nov;13(11):749-59</Citation><ArticleIdList><ArticleId IdType="pubmed">15386720</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2012 May;18(5):801-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22516189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2010 Jan 15;201(2):186-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19995265</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2011;6(9):e24384</Citation><ArticleIdList><ArticleId IdType="pubmed">21915319</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Intern Med. 2012 Mar 26;172(6):484-91</Citation><ArticleIdList><ArticleId IdType="pubmed">22371873</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Vaccin Immunother. 2012 Jul;8(7):851-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22777099</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Manitoba</li></region><settlement><li>Winnipeg</li></settlement><orgName><li>Université du Manitoba</li></orgName></list><tree><country name="Canada"><region name="Manitoba"><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name></region><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name><name sortKey="Bozat Emre, Songul" sort="Bozat Emre, Songul" uniqKey="Bozat Emre S" first="Songul" last="Bozat-Emre">Songul Bozat-Emre</name><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><name sortKey="Elliott, Lawrence" sort="Elliott, Lawrence" uniqKey="Elliott L" first="Lawrence" last="Elliott">Lawrence Elliott</name><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name><name sortKey="Hammond, Gregory" sort="Hammond, Gregory" uniqKey="Hammond G" first="Gregory" last="Hammond">Gregory Hammond</name><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name><name sortKey="Mahmud, Salaheddin M" sort="Mahmud, Salaheddin M" uniqKey="Mahmud S" first="Salaheddin M" last="Mahmud">Salaheddin M. Mahmud</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name><name sortKey="Van Caeseele, Paul" sort="Van Caeseele, Paul" uniqKey="Van Caeseele P" first="Paul" last="Van Caeseele">Paul Van Caeseele</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000234 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000234 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26600435
|texte= Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26600435" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |